Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Safia Belbachir

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Cytotherapy|December 6, 2023
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyondSafia Belbachir, Allistair Abraham, Akshay Sharma, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort studyGemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Cytotherapy|December 6, 2023
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyondSafia Belbachir, Allistair Abraham, Akshay Sharma, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 24, 2026
Persistent and pathogen-specific infection risk during long-term survivorship after CD19 CAR-T: An Australian multi-centre cohort studyGemma K Reynolds, Mark R Dowling, Safia Belbachir, et al.
Blood|February 17, 2026
Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphomaMark R Dowling, Edward Robert Scheffer Cliff, Anthony Jeffrey, et al.
Pageof 1